undamentalytics Newsletter
Sign in

Eloxx Pharmaceuticals, Inc. (ELOX) stock

Add to watchlist

Add holding +

NASDAQ: ELOX Nasdaq Biotechnology

Eloxx Pharmaceuticals, Inc. is a US-listed company in the biotechnology industry. Its financial year ends in December.

Who’s trading

What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.

  • Funds22 adding, 0 cuttingOf 2 active managers that changed their stake, 2 added; quarter to June 30, 2026Fund buyers and sellers

The Fundamentalytics view

Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.

Latest results

Share reaction
+7.5% in the first session after the results on August 11, 2026, against -0.1% for the S&P 500

Eloxx Pharmaceuticals' figures from its SEC filings and results release; estimates are the analysts' average. Not a recommendation.

Price chart

  • 1 day+0.7%
  • 1 week-3.1%
  • 1 month-16.6%

Closing prices to 2026-11-02. Price change only, dividends excluded.

Loading chart…

Third-party market data · may be delayed

At a glance

Trailing twelve months, from SEC filings

Earnings

Last results
August 11, 2026

News & updates

Updated October 31, 2026

Company announcements, filed results and changes that matter to shareholders.

  1. Leadership
  2. Results

Refreshed hourly when new source data is available. Summaries are checked against company releases and SEC filings. Company announcement headlines are labelled when a checked summary is unavailable.

Valuation

Eloxx Pharmaceuticals, Inc. valuation models and calculator

No model value for Eloxx Pharmaceuticals, Inc. at the moment. Current status: limited reported history: available models are shown without a Buy/Hold/Sell rating. Available reported financials are shown below.

Fundamentalytics rating

model v1.6 · 2026-11-03

Not rated: limited reported history: available models are shown without a Buy/Hold/Sell rating.

Valuation models

We value Eloxx Pharmaceuticals, Inc. as an operating company, with every model that fits that kind of business. Cost of equity 9.9%: the 10-year Treasury yield (4.9%) plus a beta of 1.1 times a 4.5% equity risk premium.

Value per share by model
Model Value per share In the combined value?
Price-to-earnings vs peers Earnings per share times peers' typical (harmonic-mean) price-to-earnings. — Does not apply: no twelve-month earnings or share count in the filings yet
Residual income Book value plus the present value of returns above the cost of equity, fading over ten years. — Does not apply: no twelve-month earnings or share count in the filings yet
Justified price-to-book Book value times (return on equity - growth) / (cost of equity - growth): steady-state returns. — Does not apply: no twelve-month earnings or share count in the filings yet
Revenue-to-maturity model Revenue grown to maturity with the cash margin moving to the industry's; for companies not yet profitable. — Does not apply: revenue and margins don't support a positive value
Price-to-sales vs peers Sales per share times peers' typical price-to-sales; used only when earnings are negative. — Does not apply: no twelve-month earnings or share count in the filings yet
Combined value Weighted average of the models that apply: the primary model (price-to-earnings vs peers) counts double. Models more than 5x or less than 0.2x the share price, or more than 3x away from the other models' median, are left out. — No model applies: the filings don’t yet support a value.

Different models fail in different ways, so where several apply we average them rather than trust one. Peer-based models compare Eloxx Pharmaceuticals, Inc. with Biotechnology in our coverage, using third-party market data. Model values are estimates under stated assumptions, updated as new filings arrive; not price targets or investment advice. How each model works.

Moat

Not assessed: fewer than five years of comparable figures in the filings. AI disruption exposure for this industry: Medium.

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Forecasts and guidance

Analysts' consensus

Fiscal yearEPSGrowthRevenueGrowth
Current −$2.23 +59% — —
Next −$2.55 −14% — 0%

How the EPS forecast has moved

The consensus EPS forecast for the current fiscal year is −9.7% on 90 days ago. In the last 30 days, 0 analysts raised Eloxx Pharmaceuticals, Inc.'s forecast and 1 cut it.

Consensus EPS forecast Eloxx Pharmaceuticals, Inc., last 90 days
−$4.00 −$3.00 −$2.00 −$1.00 $0.00 90 days ago 60 days ago 30 days ago 7 days ago Now Current fiscal year, 90 days ago: −$2.47 Current fiscal year, 60 days ago: −$2.85 Current fiscal year, 30 days ago: −$2.10 Current fiscal year, 7 days ago: −$2.10 Current fiscal year, Now: −$2.23 −$2.23 Next fiscal year, 90 days ago: −$3.61 Next fiscal year, 60 days ago: −$2.72 Next fiscal year, 30 days ago: −$2.72 Next fiscal year, 7 days ago: −$2.72 Next fiscal year, Now: −$2.55 −$2.55

Average of analysts' published estimates (third-party data).

View chart data
Period Current fiscal yearNext fiscal year
90 days ago −$2.47−$3.61
60 days ago −$2.85−$2.72
30 days ago −$2.10−$2.72
7 days ago −$2.10−$2.72
Now −$2.23−$2.55

Analyst recommendations

5 analysts, Oct 2026
Buy5100%
Hold00%
Sell00%

Monthly trend

  1. Oct 202655
  2. Sep 202644
  3. Aug 202633
  4. Jul 202622

Counts of recommendations published by analysts covering Eloxx Pharmaceuticals, Inc., by month. Source: Aggregated broker recommendations (third-party data). Aggregated counts only: we do not reproduce any firm's recommendation or price target, and these are not Fundamentalytics ratings.

Positioning

Short interest
1.1%
of tradable shares
Days to cover
1.74
at average volume
Short interest, 1 month
−9%
to October 15, 2026
Held by institutions
74%
of shares
Held by insiders
19.1%
of shares
Employees
10
full time

Consensus figures average analysts' published estimates (third-party data); guidance is the company's own. Neither is our forecast. Short interest is reported twice a month and lags. Market data may be delayed.

This section is general information, not investment advice or a personal recommendation, and it does not take account of your objectives or circumstances. Forecasts and guidance are estimates, not promises: companies miss their own guidance and analysts' figures are often revised. Prices can fall as well as rise, and you can lose money. See our disclaimer.

Share-price performance

Market data may be delayed

Price behaviour

52-week range
Not enough history
From 52-week high
—
vs 50-day average
−15.4%
vs 200-day average
—
Volatility (1 year)
—
Beta vs S&P 500
—

Volatility is the annualised standard deviation of daily returns. Beta 1.5 means the shares typically moved 1.5% for each 1% move in the S&P 500 over the past year. Prices to November 2, 2026.

Share price after results

Next day
1 up, 0 down
typical move ±7.5%
After a week
1 up, 0 down
typical move ±7.4%
After a month
0 up, 1 down
typical move ±4.2%
Results releasedNext dayS&P 500 next day5 days21 days
August 11, 2026 +7.5% −0.1% +7.4% −4.2%

From the close before the release date to the close 1, 5 and 21 trading days after it, so releases before the open and after the close are both captured. Past moves don't predict future ones.

Fundamentals

Data: SEC EDGAR XBRL company facts (as filed in 10-K/10-Q); forms . Generated November 3, 2026. Definitions in our methodology.

Who owns it

Funds buying and selling
Reported value
$40.2M
Institutions reporting
22
Positions opened / closed
22 / 0

Top buyers and sellers, Q2 2026: 22 institutions bought and 0 sold ; the biggest buyer was Nantahala Capital Management, LLC (+800K shares) . See which funds bought and sold →

Largest reported holders, June 30, 2026
Manager Value Shares Share of 13F value Shares QoQ
Nantahala Capital Management, LLC $11.1M 800K 27.6% —
Samsara Biocapital, LLC $5.6M 400K 13.8% —
Ecor1 Capital, LLC $5.6M 400K 13.8% —
Siren, L.L.C. $5.6M 400K 13.8% —
Aberdeen Group PLC $5.6M 400K 13.8% —
Stonepine Capital Management, LLC $5.5M 397K 13.7% —
Vanguard Capital Management LLC $1.1M 79K 2.7% —
Vanguard Fiduciary Trust Co $147,156 11K 0.4% —
Seven Grand Managers, LLC $138,800 10K 0.3% —
Morgan Stanley $21,431 2K 0.1% —
Vanguard Global Advisers, LLC $9,966 1K 0.0% —
UBS Group AG $8,842 1K 0.0% —

From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Eloxx Pharmaceuticals, Inc.'s complete shareholder register. Values are as reported by the filers .

Insider trading activity

Full insider history and chart
Insider purchases History → $0 0 trades by 0 insiders, last 12 months Insider sales History → $0 0 trades by 0 insiders
Net ▲ $0 net buying

No open-market insider trades reported in the last 12 months.

From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.

Earnings dates and SEC filings

Results announcements

  • August 11, 2026
  • November 13, 2023
  • May 16, 2023
  • April 3, 2023
  • November 14, 2022
  • August 15, 2022

Recent SEC filings

Data status

When each part of this page on Eloxx Pharmaceuticals, Inc. was last updated.

DataLast updatedSource
Share priceExchange closing prices
News and updatesCompany releases and SEC 8-K filings
Analyst estimatesAggregated analyst estimates
Valuation and scoresOur models, from the filed figures

How we build and check these figures: methodology and data sources.

Eloxx Pharmaceuticals, Inc. in brief

What does Eloxx Pharmaceuticals, Inc. do?
Eloxx Pharmaceuticals, Inc. is a US-listed company in the biotechnology industry. Its financial year ends in December.
What is Eloxx Pharmaceuticals, Inc.'s stock ticker?
Eloxx Pharmaceuticals, Inc. trades under the ticker ELOX on Nasdaq. This page brings together its financial statements, valuation models, ownership and recent company updates.
Who are Eloxx Pharmaceuticals, Inc.'s largest institutional shareholders?
By value reported in 13F filings for June 30, 2026, the largest reported holders are Nantahala Capital Management, LLC, Samsara Biocapital, LLC and Ecor1 Capital, LLC. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.